Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.

Literature DB >> 29097498

Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.

Carla Casu¹, Vania Lo Presti¹, Paraskevi Rea Oikonomidou^1,2, Luca Melchiori³, Osheiza Abdulmalik¹, Pedro Ramos⁴, Stefano Rivella⁵.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 29097498 PMCID： PMC5792284 DOI： 10.3324/haematol.2017.181511

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

14 in total

Review 1. Pathophysiology of thalassaemia.

Authors: D J Weatherall
Journal: Baillieres Clin Haematol Date: 1998-03

2. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

Authors: Ruben A Mesa
Journal: IDrugs Date: 2010-06

3. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

Authors: Ilaria V Libani; Ella C Guy; Luca Melchiori; Raffaella Schiro; Pedro Ramos; Laura Breda; Thomas Scholzen; Amy Chadburn; YiFang Liu; Margrit Kernbach; Bettina Baron-Lühr; Matteo Porotto; Maria de Sousa; Eliezer A Rachmilewitz; John D Hood; M Domenica Cappellini; Patricia J Giardina; Robert W Grady; Johannes Gerdes; Stefano Rivella
Journal: Blood Date: 2008-05-14 Impact factor: 22.113

4. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.

Authors: Stefano Rivella; Chad May; Amy Chadburn; Isabelle Rivière; Michel Sadelain
Journal: Blood Date: 2002-12-12 Impact factor: 22.113

5. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Authors: Haifa Kathrin Al-Ali; Viktoriya Stalbovskaya; Prashanth Gopalakrishna; Julian Perez-Ronco; Lynda Foltz
Journal: Leuk Lymphoma Date: 2016-02-25

Review 6. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

Authors: Stefano Rivella
Journal: Blood Rev Date: 2012-04 Impact factor: 8.250

7. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors: Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245

8. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Authors: Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Journal: Blood Date: 2010-02-03 Impact factor: 22.113

Review 9. Vascular complications after splenectomy for hematologic disorders.

Authors: Shelley E Crary; George R Buchanan
Journal: Blood Date: 2009-07-27 Impact factor: 22.113

10. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Authors: Gerlinde Wernig; Michael G Kharas; Rachel Okabe; Sandra A Moore; Dena S Leeman; Dana E Cullen; Maricel Gozo; Elizabeth P McDowell; Ross L Levine; John Doukas; Chi Ching Mak; Glenn Noronha; Michael Martin; Yon D Ko; Benjamin H Lee; Richard M Soll; Ayalew Tefferi; John D Hood; D Gary Gilliland
Journal: Cancer Cell Date: 2008-04 Impact factor: 31.743

7 in total

Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.

Review 1. Pathophysiology of thalassaemia.

2. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

3. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.

4. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.

5. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

Review 6. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

7. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

8. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Review 9. Vascular complications after splenectomy for hematologic disorders.

10. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Review 1. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia.

2. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.

Review 3. Advancing the care of β-thalassaemia patients with novel therapies.

Review 4. The Role of Iron in Benign and Malignant Hematopoiesis.

Review 5. Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders.

Review 6. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.

Review 7. Innovative Treatments for Rare Anemias.